Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.contributor.authorYasin, Ayşe İrem
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorSümbül, Bilge
dc.contributor.authorKoral, Lokman
dc.contributor.authorŞimsek, Melih
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorÖztürk, Akın
dc.contributor.authorPerkin, Perihan
dc.contributor.authorDemirtaş, Derya
dc.contributor.authorErdemoğlu, Engin
dc.contributor.authorHacıbekiroğlu, İlhan
dc.contributor.authorÇakır, Emre
dc.contributor.authorTanrıkulu, Eda
dc.contributor.authorÇoban, Ezgi
dc.contributor.authorÖzçelik, Melike
dc.contributor.authorÇelik, Sinemis
dc.contributor.authorTeker, Fatih
dc.contributor.authorAksoy, Asude
dc.contributor.authorFırat, Sedat T.
dc.contributor.authorTekin, Ömer
dc.contributor.authorKalkan, Ziya
dc.contributor.authorTürken, Orhan
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorDane, Faysal
dc.contributor.authorBilici, Ahmet
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorŞeker, Mesut
dc.contributor.authorTürk, Hacı Mehmet
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned2022-03-25T11:53:03Z
dc.date.available2022-03-25T11:53:03Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.
dc.description.sponsorshipOncological Clinical Research Association (ONKAD)en_US
dc.identifier.citationYasin, A. İ., Göktaş Aydın, S., Sümbül, B., Koral, L., Şimsek, M., Geredeli, Ç. ... Gümüş, M. (2022). Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study. Future Oncology, 18(10), 1235-1244. https://doi.org/10.2217/fon-2021-1248
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.endpage1244
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue10
dc.identifier.pmid35081732
dc.identifier.scopus2-s2.0-85126490162
dc.identifier.scopusqualityQ2
dc.identifier.startpage1235
dc.identifier.urihttps://doi.org/10.2217/fon-2021-1248
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9171
dc.identifier.volume18
dc.identifier.wos000747186600001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCancer
dc.subjectChemotherapy
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectImmunotherapy
dc.subjectMalignancy
dc.subjectSARS-CoV-2
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Aydin-Sabin-2022.pdf
Boyut:
1.37 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu